All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE
MediCom Oncology Clinical Pearls Podcasts
3 minutes 36 seconds
8 years ago
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE
Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
